SCHEMBL3353972

SCHEMBL3353972

CC[Sn](CC)(CC)c1ncco1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6416075 0.86 FAAH (0.32)
SCHEMBL13735602 0.83 FAAH (0.30)
SCHEMBL426377 0.79 FAAH (0.35)
SCHEMBL8499928 0.73
SCHEMBL28748080 0.68
SCHEMBL3371541 0.68
SCHEMBL25391442 0.64 CCR1 (0.32)
SCHEMBL27101 0.64
SCHEMBL735083 0.64
Water SCHEMBL10389199 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
EP-1499616-B1 HETEROCYCLIC COMPOUNDS ASTRAZENECA AB (SE) 2009-06-17 EP disclosed
US-7417050-B2 Cognition activators; Alzheimer's disease; attention deficit disorders; Parkinson's disease; Huntington's disease; neurodegenerative disease ASTRAZENECA AB (SE) 2008-08-26 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-20050131003-A1 Heterocyclic compounds ASTRAZENECA AB (SE) 2005-06-16 US disclosed
EP-1499616-A1 HETEROCYCLIC COMPOUNDS AstraZeneca AB (SE) 2005-01-26 EP disclosed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP disclosed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US disclosed
WO-2003087104-A1 HETEROCYCLIC COMPOUNDS ASTRAZENECA AB (SE) 2003-10-23 WO disclosed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO disclosed